The melanoma & skin cancer condition center is a comprehensive resource for clinical news and expert insights on melanoma & skin cancer. Read more at OncLive.
November 22nd 2024
A biologics license application was submitted to the FDA seeking the approval of RP1 plus nivolumab for patients with PD-1 inhibitor–exposed melanoma.
Douglas B. Johnson, MD, MSCI, unpacks NCCN guideline updates in melanoma, detailing how neoadjuvant and TIL therapies have been notable advancements.
November 21st 2024
Matthew P. Deek, MD, discusses multidisciplinary approaches in treating locally advanced basal cell carcinoma.
November 16th 2024
New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.
November 11th 2024
RP1 plus nivolumab generated responses in advanced melanoma that progressed on or after prior anti–PD-1 therapy.
The investigational PRAME-targeted T-cell therapy IMA203 generated responses in melanoma and other solid tumors,
E-602 plus cemiplimab elicited preliminary antitumor activity and had a tolerable safety profile in PD-(L)1–resistant solid tumors.
November 7th 2024
Radiomic biomarkers can predict treatment response through assessments of tumor growth in patients with metastatic uveal melanoma treated with roginolisib.
Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial of early switch from targeted therapy to immunotherapy in advanced BRAF V600–positive melanoma.
November 2nd 2024
Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.
November 1st 2024
Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.
This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.
October 30th 2024
Treatment options after progression on anti–PD-1 and BRAF/MEK inhibitors have been limited but TIL therapy has expanded metastatic melanoma treatment.
October 10th 2024
IMA203, a TCR-T agent targeting PRAME, was safe and effective in patients with heavily pretreated melanoma.
October 7th 2024
Thach-Giao Truong, MD, discusses the ImmunoCobiVem trial investigating the switch from targeted therapy to immunotherapy in advanced BRAF V600+ melanoma.
September 26th 2024
Alexander C. Van Akkooi, MD, PhD, FRACS, discusses the prognostic value of minimal sentinel node tumor burden in melanoma.
Meredith McKean, MD, discusses the efficacy of fianlimab given in combination with cemiplimab for patients with advanced melanoma.
September 18th 2024
Richard Vile, PhD, explains how CAR-T cell therapy works, including the benefits, risks and realities of treatment.
September 16th 2024
Fianlimab plus cemiplimab demonstrated persistent and significant clinical activity in patients with advanced melanoma.
September 15th 2024
Early switch therapy to atezolizumab after run-in with vemurafenib plus cobimetinib led to improved 4- and 5-month OS rates in BRAF V600–positive melanoma.